Table 3 Cardiac characteristics at enrollment in symptomatic patients with a predominantly cardiac or mixed phenotype
ATTRwt amyloidosis (n = 1410) | ATTRv amyloidosis (n = 3017) | |
|---|---|---|
Heart failure, n (%) | 1227 (87.0) | 787 (72.3) |
NYHA functional classa, n (%) | ||
I | 126 (10.5) | 111 (14.2) |
II | 729 (60.9) | 392 (50.2) |
III | 315 (26.3) | 246 (31.5) |
IV | 27 (2.3) | 32 (4.1) |
Abnormal ECG, n (%) | 1170 (83.0) | 670 (61.6) |
Atrial fibrillation/flutter, n (%) | 509 (36.1) | 114 (10.5) |
Pacemaker implanted, n (%) | 216 (15.3) | 65 (6.0) |
ICD implanted, n (%) | 73 (5.2) | 28 (2.6) |
NT-proBNP (pg/mL) | n = 707 | n = 255 |
Median (10th, 90th percentiles) | 2146.0 (526.0, 6312.0) | 1791.0 (229.0, 6627.0) |
Troponin I (ng/mL) | n = 112 | n = 97 |
Median (10th, 90th percentiles) | 0.1 (0.0, 0.3) | 0.1 (0.0, 0.5) |
Troponin T (ng/mL) | n = 270 | n = 164 |
Median (10th, 90th percentiles) | 0.0 (0.0, 0.1) | 0.0 (0.0, 0.2) |